Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Adenocarcinoma in Situ
  • Carcinoma, Squamous Cell
  • Cervical Intraepithelial Neoplasia
  • Human Papillomavirus DNA Tests
  • Papillomavirus Infections
  • Squamous Intraepithelial Lesions of the Cervix
  • Uterine Cervical Neoplasms

abstract

  • Although both the Cobas and Aptima platforms offer highly sensitive tests for high-grade cervical lesions, Aptima HPV testing demonstrated significantly higher specificity and positive predictive value than Cobas testing for biopsy-confirmed ≥HSIL. The considerable difference may be related to the significant increase in E6/E7 expression after HPV DNA integration. The significantly higher specificity and overall accuracy of Aptima testing for ≥HSIL, resulting in the identification of high-risk populations that require immediate treatment and close follow-up, may prove useful in clinical risk stratification. Cancer Cytopathol 2017. © 2017 American Cancer Society.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncy.21875

PubMed ID

  • 28574670

Additional Document Info